{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Triple-Negative+Breast+Cancer",
    "query": {
      "condition": "Metastatic Triple-Negative Breast Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 364,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Triple-Negative+Breast+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T08:48:47.397Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02900664",
      "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        },
        {
          "name": "ACZ885",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CJM112",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TMT212",
          "type": "DRUG"
        },
        {
          "name": "EGF816",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 283,
      "start_date": "2016-08-23",
      "completion_date": "2021-03-17",
      "has_results": false,
      "last_update_posted_date": "2022-03-29",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900664"
    },
    {
      "nct_id": "NCT06894771",
      "title": "A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "MK-4700",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2025-04-23",
      "completion_date": "2025-12-08",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 2,
      "location_summary": "Hackensack, New Jersey • San Antonio, Texas",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06894771"
    },
    {
      "nct_id": "NCT06449222",
      "title": "Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Breast Cancer",
        "Triple Negative Breast Cancer",
        "Metastatic Triple Negative Breast Cancers"
      ],
      "interventions": [
        {
          "name": "BNT327 Dose Level 1 (DL1)",
          "type": "DRUG"
        },
        {
          "name": "BNT327 Dose Level 1 (DL2)",
          "type": "DRUG"
        },
        {
          "name": "Nab-placlitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "BNT327 Optimized Dose",
          "type": "DRUG"
        },
        {
          "name": "BNT327 Equivalent Q3W Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioNTech SE",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2024-08-26",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-25",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 13,
      "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06449222"
    },
    {
      "nct_id": "NCT01576666",
      "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dose Escalation",
        "Safety",
        "Preliminary Efficacy",
        "Advanced Solid Tumors",
        "Metastatic Breast Cancer",
        "Advanced Pancreatic Adenocarcinoma",
        "Metastatic Colorectal Cancer",
        "Recurrent Glioblastoma Multiforme",
        "Gastric Cancer",
        "Gastroesophageal Junction Cancer",
        "Triple Negative Metastatic Breast Cancer",
        "Hormone Receptor Positive (ER+/PR+, and Her2-) Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "LDE225",
          "type": "DRUG"
        },
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2012-07",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2020-12-19",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01576666"
    },
    {
      "nct_id": "NCT05570253",
      "title": "A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "SDX-7320",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2022-10-03",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Atlanta, Georgia • Basking Ridge, New Jersey + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570253"
    },
    {
      "nct_id": "NCT01272141",
      "title": "A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Breast Cancer",
        "Cancer of the Breast"
      ],
      "interventions": [
        {
          "name": "Lapatinib and Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2010-12",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2014-09-22",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272141"
    },
    {
      "nct_id": "NCT03454451",
      "title": "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Renal Cell Cancer",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "Cervical Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Endometrial Cancer",
        "Sarcoma",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Bladder Cancer",
        "Metastatic Castration Resistant Prostate Cancer",
        "Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "CPI-006",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + ciforadenant",
          "type": "DRUG"
        },
        {
          "name": "CPI-006 + pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corvus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 117,
      "start_date": "2018-04-25",
      "completion_date": "2023-02-19",
      "has_results": false,
      "last_update_posted_date": "2023-12-21",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 22,
      "location_summary": "Tucson, Arizona • Duarte, California • San Francisco, California + 18 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03454451"
    },
    {
      "nct_id": "NCT03853707",
      "title": "Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Prognostic Stage IV Breast Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2019-03-04",
      "completion_date": "2023-09-19",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03853707"
    },
    {
      "nct_id": "NCT03094169",
      "title": "AVID100 in Advanced Epithelial Carcinomas",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AVID100 IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Formation Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2017-02-01",
      "completion_date": "2021-01-30",
      "has_results": true,
      "last_update_posted_date": "2025-06-11",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 10,
      "location_summary": "New Haven, Connecticut • Grand Rapids, Michigan • New York, New York + 6 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03094169"
    },
    {
      "nct_id": "NCT04315233",
      "title": "Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Recurrent Ovarian Carcinoma"
      ],
      "interventions": [
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Belinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2021-05-03",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-06-10T08:48:47.397Z",
      "location_count": 2,
      "location_summary": "Salt Lake City, Utah • Fairfax, Virginia",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04315233"
    }
  ]
}